Aethlon Medical (NASDAQ: AEMD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.
Volatility & Risk
Aethlon Medical has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Valuation and Earnings
This table compares Aethlon Medical and Eyepoint Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||136.15||-$5.67 million||($0.46)||-2.49|
|Eyepoint Pharmaceuticals||$7.54 million||15.76||-$18.48 million||($0.52)||-4.23|
Aethlon Medical has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and recommmendations for Aethlon Medical and Eyepoint Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aethlon Medical currently has a consensus target price of $3.00, indicating a potential upside of 161.48%. Eyepoint Pharmaceuticals has a consensus target price of $5.75, indicating a potential upside of 161.36%. Given Aethlon Medical’s higher probable upside, analysts plainly believe Aethlon Medical is more favorable than Eyepoint Pharmaceuticals.
Institutional & Insider Ownership
7.0% of Aethlon Medical shares are held by institutional investors. Comparatively, 24.1% of Eyepoint Pharmaceuticals shares are held by institutional investors. 6.6% of Aethlon Medical shares are held by insiders. Comparatively, 18.9% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Aethlon Medical and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aethlon Medical beats Eyepoint Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Aethlon Medical Company Profile
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.